For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.

A newly discovered link between pancreatic cancer and neural signaling reveals a promising drug target that slows tumor ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

Moving gemcitabine/nab-paclitaxel to every-other-week dosing decreases infusion visits and may lessen cumulative toxicity, ...

New @hopkinskimmel research finds extra copies of chromosome 1q may drive the earliest stages of pancreatic cancer. › ...

A new UCLA investigator-initiated study has found that adding immunotherapy to standard chemotherapy before surgery is safe ...

Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.

Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult ...

Ben Sasse broke down in tears while discussing his faith and stage-four pancreatic cancer diagnosis during a recent interview ...

An experimental drug combination was able to effectively treat pancreatic cancer in mouse models without tumor resistance.

Scientists have uncovered a hidden partnership between pancreatic cancer and the nervous system. Support cells in the ...